Trial Profile
A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Nov 2011
Price :
$35
*
At a glance
- Drugs CV 301 (Primary)
- Indications Advanced breast cancer; Breast cancer; Ovarian cancer
- Focus Therapeutic Use
- 11 Nov 2011 New trial record
- 08 Nov 2011 Results published in the Clinical Cancer Research journal, according to a Bavarian Nordic media release. Results were also reported in the media release.